



SEQUENCE LISTING

<110> MATSUTANI, Etsuya
NAITO, Kenichiro

<120> Agents for Retarding Change of Hormone-dependent Cancer into
Hormone-independent Cancer

<130> 2556US0P

<140> US 09/806,125

<141> 2001-03-28

<150> PCT/JP99/05533

<151> 1999-10-07

<150> JP 10-286793

<151> 1998-10-08

<160> 15

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> LH-RH agosist 'leuprorelin'.

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> The 'Xaa' at location 1 stands for 5-oxo-L-proline.

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> The 'Xaa' at location 6 stands for DLeu.

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> The 'Xaa' at location 9 stands for N-ethyl-L-prolinamide.

<400> 1

Xaa His Trp Ser Tyr Xaa Leu Arg Xaa
1 5

<210> 2

<211> 9

RECEIVED
JUN 04 2003
TECH CENTER 1600/2900

<212> PRT
<213> Artificial Sequence

<220>
<223> Oligopeptide designed to act as LH-RH agonist.

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> The 'Xaa' at location 1 stands for 5-oxo-L-proline.

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> The 'Xaa' at location 6 stands for DLeu, DAla, DTrp, DSer(tBu), D2Nal, or DHis(ImBzl).

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> The 'Xaa' at location 9 stands for N-ethyl-L-prolinamide.

<400> 2

Xaa His Trp Ser Tyr Xaa Leu Arg Xaa
1 5

DR
cut
<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Oligopeptide designed to act as LH-RH agonist.

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> The 'Xaa' at location 1 stands for 5-oxo-L-proline.

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> The 'Xaa' at location 6 stands for DLeu, DAla, DTrp, DSer(tBu), D2Nal, or DHis(ImBzl).

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> The 'Xaa' at location 10 stands for L-glycinamide.

<400> 3

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa
1 5 10

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Oligopeptide designed to act as LH-RH antagonist.

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> The 'Xaa' at location 1 stands for N(4H2-furoyl)Gly.

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> The 'Xaa' at location 2 stands for D2Nal.

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> The 'Xaa' at location 3 stands for D4ClPhe.

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> The 'Xaa' at location 4 stands for D3Pal.

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> The 'Xaa' at location 6 stands for NMeTyr, Tyr, Aph(Atz),
or NMeAph(Atz).

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> The 'Xaa' at location 7 stands for DLys(Nic), DCit,
DLys(AzaglyNic), DLys(AzaglyFur), DhArg(Et2), DAph(Atz) or DhCi.

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> The 'Xaa' at location 9 stands for Lys(Nisp), Arg or hArg(Et2).

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> The 'Xaa' at location 11 stands for D-alaninamide.

<400> 4

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1 5 10

<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Oligopeptide designed to act as LH-RH antagonist.

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> The 'Xaa' at location 1 stands for N-acetyl-3-(2-naphthyl)-D-alanine.

D/L
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> The 'Xaa' at location 2 stands for D4ClPhe.

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> The 'Xaa' at location 3 stands for D3Pal.

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> The 'Xaa' at location 5 stands for NMeTyr, Tyr, Aph(Atz), or NMeAph(Atz).

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> The 'Xaa' at location 6 stands for DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur), DhArg(Et2), DAph(Atz) or DhCi.

<220>
<221> MISC_FEATURE

<222> (8)..(8)
<223> The 'Xaa' at location 8 stands for Lys(Nisp), Arg or hArg(Et2).

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> The 'Xaa' at location 10 stands for D-alaninamide.

<400> 5

Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1 5 10

<210> 6
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino acid sequence common to kinase regions of receptor type tyrosine kinases.

<400> 6

His Arg Asp Leu Ala Ala
1 5

DJ <210> 7
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<223> Amino acid sequence common to kinase regions of receptor type tyrosine kinases.

<400> 7

Ser Asp Val Trp Ser
1 5

<210> 8
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA

fragment of EGF receptor-like kinase.

<400> 8
caymgggayy tggchgc 17

<210> 9
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of EGF receptor-like kinase.

<400> 9
arctccamac rtcrct 16

<210> 10
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of insulin receptor-like kinase.

<400> 10
caymrggacy tkgcwgc 17

<210> 11
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of insulin receptor-like kinase.

<400> 11
arctccamac gtcnga 16

<210> 12
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of PDGF or FGF receptor-like kinase.

<400> 12
caymrggacy tggcrgc 17

<210> 13
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of PDGF or FGF receptor-like kinase.

<400> 13
argaccasac rtrcrt 16

<210> 14
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of beta-actin.

<400> 14
atctggcacc acaccttcta caatgagctg cg 32

<210> 15
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide designed to act as primer for amplifying cDNA
fragment of beta-actin.

<400> 15
cgtcatactc ctgcttgctg atccacatct gc 32